Licensing · GCC · Announced 7 Oct 2026
Elpen → ADCAN Pharma
Licensing deal between Elpen and ADCAN Pharma, announced 7 Oct 2026.
Parties: ELPEN → ADCAN PHARMA
- Deal type
- Licensing
- Value
- Not stated
- Territory
- UAE, KSA and rest of Middle East (per the five-deal umbrella terms)
- Therapeutic area
- Oncology
- Asset
- Strategic agreement focused on expanding ADCAN's Oncology therapy area — licensing and technology transfer; specific molecules undisclosed
- Announced
- 7 Oct 2026
Our analysis
Why this matters
This is a capability deal disguised as a portfolio deal.
Elpen — Greece's leading pharmaceutical company (founded 1965; 1,800+ employees; 90+ export countries; 30+ proprietary preparations; 15% of turnover reinvested in R&D) — is building a new high-potency API (HPAPI) oncology plant at Tripoli for oral solid doses.
The full analysis is free to read with a work email on this page.
Source: ADCAN